Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.

Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW.

Mol Cell Biol. 2001 Oct;21(19):6470-83.

2.

Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.

Heibert SW, Lutterbach B, Durst K, Wang L, Linggi B, Wu S, Wood L, Amann J, King D, Hou Y.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S31-4. Review.

PMID:
11587363
3.

ETO interacting proteins.

Hug BA, Lazar MA.

Oncogene. 2004 May 24;23(24):4270-4. Review.

PMID:
15156183
4.

The ETO (MTG8) gene family.

Davis JN, McGhee L, Meyers S.

Gene. 2003 Jan 16;303:1-10. Review.

PMID:
12559562
5.

AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.

Choi Y, Elagib KE, Goldfarb AN.

Crit Rev Eukaryot Gene Expr. 2005;15(3):207-16. Review.

PMID:
16390317
6.

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

Licht JD.

Oncogene. 2001 Sep 10;20(40):5660-79. Review. No abstract available.

7.

N-CoR-HDAC corepressor complexes: roles in transcriptional regulation by nuclear hormone receptors.

Jones PL, Shi YB.

Curr Top Microbiol Immunol. 2003;274:237-68. Review.

PMID:
12596910
8.

Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO.

Hiebert SW, Downing JR, Lenny N, Meyers S.

Curr Top Microbiol Immunol. 1996;211:253-8. Review. No abstract available.

PMID:
8585956
9.

Eloquent silence: developmental functions of Class I histone deacetylases.

Cunliffe VT.

Curr Opin Genet Dev. 2008 Oct;18(5):404-10. doi: 10.1016/j.gde.2008.10.001. Epub 2008 Oct 16. Review.

10.

Role of nuclear receptor corepressors in leukemogenesis.

Guidez F, Zelent A.

Curr Top Microbiol Immunol. 2001;254:165-85. Review. No abstract available.

PMID:
11190573
11.

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.

Imai Y, Maru Y, Tanaka J.

Cancer Sci. 2016 Nov;107(11):1543-1549. doi: 10.1111/cas.13062. Epub 2016 Nov 4. Review.

12.

An expanding job description for Blimp-1/PRDM1.

Bikoff EK, Morgan MA, Robertson EJ.

Curr Opin Genet Dev. 2009 Aug;19(4):379-85. doi: 10.1016/j.gde.2009.05.005. Epub 2009 Jul 9. Review.

PMID:
19592232
13.

Class IIA HDACs in the regulation of neurodegeneration.

Majdzadeh N, Morrison BE, D'Mello SR.

Front Biosci. 2008 Jan 1;13:1072-82. Review.

14.

Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease.

Mathias RA, Guise AJ, Cristea IM.

Mol Cell Proteomics. 2015 Mar;14(3):456-70. doi: 10.1074/mcp.O114.046565. Epub 2015 Jan 23. Review.

15.

Targeting Class I Histone Deacetylases in a "Complex" Environment.

Millard CJ, Watson PJ, Fairall L, Schwabe JW.

Trends Pharmacol Sci. 2017 Apr;38(4):363-377. doi: 10.1016/j.tips.2016.12.006. Epub 2017 Jan 28. Review.

PMID:
28139258

Supplemental Content

Support Center